Results 141 to 150 of about 4,730,461 (228)

The Lupus Damage Index Revision Program: Results From the Item Generation and Reduction Phases

Arthritis Care &Research, Volume 78, Issue 10, Page 1449-1466, October 2026.
Objective A data‐driven and expert/patient consensus‐based project to develop a revised Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index (SDI) is under way supported by SLICC, ACR, and the Lupus Foundation of America. Our objective is to report the item generation and reduction phase results
Burak Kundakci, Megan R. W. Barber, Ann E. Clarke, Sindhu R. Johnson, Anselm Mak, Hermine I. Brunner, Murat Inanc, Rosalind Ramsey‐Goldman, Guillermo Ruiz‐Irastorza, Ellen M. Ginzler, John G. Hanly, Alexandra Legge, Cynthia Aranow, Laurent Arnaud, Nathalie Costedoat‐Chalumeau, Dafna D. Gladman, Søren Jacobsen, Michelle Petri, Clovis A. Silva, Évelyne Vinet, Alexandre E. Voskuyl, SDI Revision Literature Review Groups, SDI Revision Delphi Panel, SDI Revision Item Reduction Committee, SDI Revision Clinical Domain Groups, Ian N. Bruce   +25 more
wiley   +1 more source

Comparing the Efficacy of Monthly Cyclophosphamide as Monotherapy versus Daily Fingolimod in Relapsing Remitting and Secondary Progressive Multiple Sclerosis

مجله دانشکده پزشکی اصفهان, 2017
Background: The aim of this study was to determine the efficacy of monthly cyclophosphamide and daily fingolimod in treatment of patients with multiple sclerosis (MS) and to compare these two treatment strategies.
Vahid Shaygannezhad, Hassan Amini
doaj  

POEMS Syndrome: 2026 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, Volume 101, Issue 10, Page 2632-2651, October 2026.
ABSTRACT Disease Overview POEMS syndrome is a life‐threatening syndrome due to an underlying plasma cell neoplasm. The major criteria for the syndrome are polyneuropathy, clonal plasma cell disorder (PCD), sclerotic bone lesions, elevated vascular endothelial growth factor, and the presence of Castleman disease.
Angela Dispenzieri
wiley   +1 more source

Examination of High-Level Language Skills in 2 Phases of Multiple Sclerosis (Relapsing-Remitting & Secondary Progressive) in Comparison With Healthy Counterparts. [PDF]

Med J Islam Repub Iran
Rahimifar P, Isazadeh R, Soltani M, Ghobadi R, Boazar A, Abaeian G, Aliabdi L, Majdinasab N, Amini P.   +8 more
europepmc   +1 more source

Current advances in 2025: A critical review of selected topics by the Association for the Advancement of Blood and Biotherapies (AABB) Clinical Transfusion Medicine Committee

Transfusion, EarlyView.
Nabiha H. Saifee, Jennifer Andrews, Mary Berg, Stella T. Chou, Mischa Covington, Elizabeth P. Crowe, Ruchika Goel, Juliana A. Guarente, Tina Ipe, Jeremy W. Jacobs, Jessica Jacobson, Cyril Jacquot, Jenna Khan, Thane A. Kubik, Theodros Mamo, Michael F. Murphy, Kerry O'Brien, Monica B. Pagano, Anil K. Panigrahi, Jacqueline N. Poston, Scott E. Potter, Simon J. Stanworth, Moritz Stolla, Alyssa Ziman, Ryan A. Metcalf   +24 more
wiley   +1 more source

From Marginal to Central: Marginal Zone‐like B Cells as Critical Targets in Cladribine‐Treated Multiple Sclerosis

Annals of Neurology, Volume 100, Issue 4, Page 808-823, October 2026.
Objective Multiple sclerosis (MS) is a chronic autoimmune disease where B cells play a central pathogenic role. Cladribine, an oral therapy, provides durable benefits by reshaping lymphocyte populations, yet its specific long‐term impact on distinct B‐cell subsets is not fully understood.
Marta Pirronello, Mario Picozza, Gisella Guerrera, Silvia Corbisiero, Andrea Misiti, Roberta C. Placido, Alice Verdiani, Lorenzo de Marco, Manolo Sambucci, Elena Olivieri, Daniela F. Angelini, Esmeralda Quartuccio, Luca Prosperini, Carla Tortorella, Maria C. Buscarinu, Valeria Zancan, Francesca de Masi, Marco Salvetti, Claudio Gasperini, Giovanna Borsellino, Luca Battistini   +20 more
wiley   +1 more source

Comparable Infection Risk of Ocrelizumab and Rituximab in Multiple Sclerosis in a Nationwide Swedish Cohort Study

Annals of Neurology, Volume 100, Issue 4, Page 788-792, October 2026.
In multiple sclerosis (MS), anti‐CD20 therapies have been associated with increased infection risk, but whether this risk differs between rituximab and ocrelizumab is not known. Using a nationwide cohort, we studied infection risk and relapse outcomes among 16,872 treatment episodes with rituximab, ocrelizumab, or other disease‐modifying therapies ...
Thomas Frisell, Sebastian Hedberg, Fredrik Piehl   +2 more
wiley   +1 more source

Long Term Follow Up of Hereditary Thrombotic Thrombocytopenic Purpura on Plasma Therapy for 9 Years: A Case Report

Clinical Case Reports, Volume 14, Issue 10, October 2026.
ABSTRACT A 7.6‐year‐old boy with hTTP had fever‐induced hemorrhagic rash, MAHA, cerebral infarction, and renal impairment. After plasma therapy, symptoms were partially relieved; 9‐year follow‐up showed regular plasma transfusion was needed, with CKD Stage 3.
Dai Xiaomei, Chen Ruyue, Wu Shuang, Tang Hanyun, Lin Qiang, Li Xiaozhong   +5 more
wiley   +1 more source

Autologous haematopoietic stem cell transplantation stabilizes retinal atrophy in multiple sclerosis. [PDF]

Brain Commun
Zoellin JRT, Mattle DE, Agostino D, Fierz FC, Ruder J, Zaugg A, Herwerth M, Weller M, Saidha S, Schippling S, Jelcic I, Roth P, Martin R, Kana V.   +13 more
europepmc   +1 more source

Harnessing Natural Killer Cells: From Neuroimmunology to Novel Therapies for Central Nervous System Diseases

MedComm, Volume 7, Issue 10, October 2026.
This review delineates the multifaceted roles of natural killer (NK) cells in the central nervous system, spanning direct cytolysis, immunoregulation, and crosstalk with the brain microenvironment. We evaluate the translational potential and challenges of NK cell immunotherapies for a spectrum of neurological conditions.
Kaihang Deng, Wai Po Chong
wiley   +1 more source